Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (78)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by GLATTRE, E
Right arrow Articles by AASETH, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GLATTRE, E
Right arrow Articles by AASETH, J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1989 Oxford University Press

research-article

Prediagnostic Serum Selenium in a Case-Control Study of Thyroid Cancer

E GLATTRE*, Y THOMASSEN**, S Ø THORESEN*, T HALDORSEN*, P G LUND-LARSEN{dagger}, L THEODORSEN{dagger} and J AASETH{ddagger}

*Cancer Registry of Norway Montebello, 0310 Oslo 3, Norway.
**National Institute of Occupational Health Gydas v. 8, 0363 Oslo 3, Norway.
{dagger}JANUS Committee, Norwegian Cancer Society Rikshospitalet Institute of Biochemistry 0027 Oslo 1, Norway.
{ddagger}Tromsø Region Hospital 9012 Tromsø, Norway.

Glattre E (Cancer Registry of Norway, Montebello, 0310 Oslo 3, Norway), Thomassen Y, Thoresen S Ø, Haldorsen T, Lund-Larsen P G, Theodorsen L and Aaseth J. Prediagnostic serum selenium in a case-control study of thyroid cancer. International Journal of Epidemiology 1989, 18: 45–49.

Sera from 43 persons who developed thyroid cancer on an average 4.8 years after blood sampling were compared with sera from controls. Three controls per case matched for sex, age, place of residence and year of blood sampling, with regard to serum selenium and serum copper. Cases were significantly lower in serum selenium than controls, and the estimated odds ratio of thyroid cancer increased from 1 for levels≥1.65 µmol/l, to 6.1 for levels 1.26–1.64 µmol/l, to 7.7 for levels ≤1.25 µmol/l. When time from blood sampling to diagnosis of the case was considered, it could be shown that the protective effect of high serum selenium concentrations was restricted to the last (<7) years prior to the diagnosis of thyroid cancer. The serum selenium concentration of cases tended to decrease relative to controls the shorter time was from blood sampling to the diagnosis.

There was no difference between cases and controls with regard to serum copper.

Revised 1 September 1988


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
Z. Li, L. Carrier, and B. G. Rowan
Methylseleninic acid synergizes with tamoxifen to induce caspase-mediated apoptosis in breast cancer cells
Mol. Cancer Ther., September 1, 2008; 7(9): 3056 - 3063.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
M. P Rayman, A. J Thompson, B. Bekaert, J. Catterick, R. Galassini, E. Hall, M. Warren-Perry, and G. J Beckett
Randomized controlled trial of the effect of selenium supplementation on thyroid function in the elderly in the United Kingdom
Am. J. Clinical Nutrition, February 1, 2008; 87(2): 370 - 378.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Song, N. Driessens, M. Costa, X. De Deken, V. Detours, B. Corvilain, C. Maenhaut, F. Miot, J. Van Sande, M.-C. Many, et al.
Roles of Hydrogen Peroxide in Thyroid Physiology and Disease
J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3764 - 3773.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. R. Marshall, W. Sakr, D. Wood, D. Berry, C. Tangen, F. Parker, I. Thompson, S. M. Lippman, R. Lieberman, D. Alberts, et al.
Design and Progress of a Trial of Selenium to Prevent Prostate Cancer among Men with High-Grade Prostatic Intraepithelial Neoplasia.
Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1479 - 1484.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. G. Fakih, L. Pendyala, P. F. Smith, P. J. Creaven, M. E. Reid, V. Badmaev, R. G. Azrak, J. D. Prey, D. Lawrence, and Y. M. Rustum
A Phase I and Pharmacokinetic Study of Fixed-Dose Selenomethionine and Irinotecan in Solid Tumors
Clin. Cancer Res., February 15, 2006; 12(4): 1237 - 1244.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Kohrle, F. Jakob, B. Contempre, and J. E. Dumont
Selenium, the Thyroid, and the Endocrine System
Endocr. Rev., December 1, 2005; 26(7): 944 - 984.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Cao, F. A. Durrani, and Y. M. Rustum
Selective Modulation of the Therapeutic Efficacy of Anticancer Drugs by Selenium Containing Compounds against Human Tumor Xenografts
Clin. Cancer Res., April 1, 2004; 10(7): 2561 - 2569.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. J. Duffield-Lillico, M. E. Reid, B. W. Turnbull, G. F. Combs Jr., E. H. Slate, L. A. Fischbach, J. R. Marshall, and L. C. Clark
Baseline Characteristics and the Effect of Selenium Supplementation on Cancer Incidence in a Randomized Clinical Trial: A Summary Report of the Nutritional Prevention of Cancer Trial
Cancer Epidemiol. Biomarkers Prev., July 1, 2002; 11(7): 630 - 639.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.